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Somatostatin is a tetradecapeptide with potent inhibitory
actions on several endocrine systems; it blocks the release of
growth hormone, follicle stimulating hormone and
thyrotropin from the pituitary gland (Krulich et al., 1968;
Brazeau et al., 1973; Hall et al., 1978; Reichlin, 1983) and
several peptide hormones from the endocrine gut and
pancreas (Cohen et al., 1978; Gerich, 1981). It also affects
exocrine and other functions of the gut, i.e. inhibits motility
and absorption and decreases gut blood flow (cf. Arnold &
Lankisch, 1980). Somatostatin also inhibits flushing in the
carcinoid syndrome by reducing peripheral serotonin (5-HT)
levels (Frolich et al., 1978).
Recently synthetic somatostatin analogues have become
available. Such compounds have been used both chronically
and acutely to relieve symptoms caused by excessive
secretion of tumour products (biogenic amines, peptide
hormones) from carcinoid lesions of the gastrointestinal tract
(cf. Bloom & Greenwood, 1985; Kvols et al., 1985). Such
analogues may act at several levels, i.e. impaired release of
tumour products, interaction with released peptides,
blockade or desensitation of tumour receptors.
With clinical experience of one somatostatin analogue
(SMS 201-995) in the chronic management of patients with
carcinoid tumours (Ahlman & Tisell, 1987) we evaluated the
usefulness of this drug in combination with peripheral
blockade of 5-HT2-receptors in a patient who had reacted
with a carcinoid crisis (flushing and profound hypotension)
at a previous attempt at anaesthesia.
A 52-year old woman with bouts of diarrhoea, slight facial flushing
and pain in the left lower abdominal quadrant was scheduled for
curettage of the uterus. After induction of anaesthesia (penotothal,
alloferin, 02/N20) she had a rapid fall in arterial blood pressure
and a red flush reaction on her face and anterior chest wall. The
peripheral pulses were impalpable for 20min. There were no signs
typical of an anaphylactic reaction, but she was treated with
antihistamines and hydrocortisone as well as fluid resuscitation. The
anaesthetist suspected a carcinoid crisis on clinical grounds and
wisely withheld therapy with adrenergic drugs.
Further work-up ofthis patient revealed a normal cardiopulmonary
function, multiple small intestinal tumours, an enlarged liver with
metastases bilaterally and very high levels of 5-hydroxyindoleacetic
acid (5-HIAA; 1000jmol 24h-1, ref. 0-50) compatible with the
midgut carcinoid syndrome. At admission to our unit her fasting
5-HT levels in peripheral whole blood were very high (856-
999ngml-1) compared with normal (<160ngml-1) (Table I). In
order to suppress the basal secretion of 5-HT from the carcinoid
lesions she was treated with a long-acting somatostatin analogue
(SMS 201-995, Sandoz, Basle, Switzerland) injected s.c. for 3 days
without convincing biochemical effect (Table I). Therefore the dose
of SMS 201-995 was doubled for the next 3 days. During this
treatment she was completely relieved of her symptoms and the
basal levels of 5-HT were significantly depressed. This patient was
then subjected to a provocative test using pentagastrin (PG)
(0.6pgkg-1 i.v.) to cause release of 5-HT from the carcinoid lesions
(cf. Ahlman et al., 1985). During provocation there was no sympto-
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matic reaction, but biochemically slowly increasing levels of 5-HT
were demonstrated (Table I). To avoid adverse reactions of 5-HT at
surgery/anaesthesia she was also treated with peripheral blockade of
5-HT2-receptors using ketanserin (Janssen Pharmaceuticals, Beerse,
Belgium) (cf. Ahlman et al., 1985). During surgery (ileocecal
resection with microdissection of metastatic lymph nodes around the
superior mesenteric artery, left sided salpingo-oophorectomy,
prophylactic cholecystectomy and surgical division of collaterals in
the hepatic ligaments prior to future embolisation therapy) and on
the first post-operative day she was given a total dose of SMS
201-995 of 400,ug daily (100ugx4s.c.) in addition to ketanserin
(20mgx2i.v.). Surgery was uneventful. During convalescence this
patient injected herself daily with SMS 201-995 50.ugx2s.c. Four
weeks later she had almost normal basal levels of 5-HT, while
urinary 5-HIAA was still elevated (589jmol 24h-1; ref. 0-50). She
was essentially symptom-free when she returned for embolisation of
the right hepatic artery. Broad spectrum antibiotics were given
preoperatively (cf. Maton et al., 1983). Embolisation was monitored
by fluoroscopy and the procedure was terminated when injected
contrast medium stayed in main arterial branches for more than
30sec (Lunderquist et al., 1982). Identical treatment with SMS 201-
995 and ketanserin was given in conjunction with this procedure as
during previous surgery. Slight flush, but no blood pressure reaction,
was seen at embolisation. Since the arterial blood pressure remained
stable, an epidural anaesthetic with marcaine (4%) was applied for
analgesia. During the following 6 week period the patient was
continuously treated with SMS 201-995 (50jgx2s.c.). She
developed slight steatorrhea probably due to suppression of
pancreatic exocrine secretion by the somatostatin analogue, which
was effectively treated with substitution of pancreatic enzymes.
Before the left hepatic artery was embolised, this patient underwent
a second PG-test, which demonstrated normal basal levels of 5-HT
and no release reaction (Table I). She had identical perioperative treat-
ment with SMS 201-995 and ketanserin at the second embolisation,
which was also uneventful. One week after completion of the
surgical and embolisation treatment SMS 201-995 was withdrawn
to evaluate the therapeutic effects. The patient remained symptom-
free and had normal 5-HT levels before and after provocation
with PG, while 5-HIAA levels were still elevated (Table I).
A cell suspension with high viability (91%) was prepared
from this tumour to investigate the type of adrenoceptors
involved in the release of 5-HT (cf. Nilsson et al., 1986).
One suspension of tumour cells (12 x 106cellsml-1) was
incubated in Kreb's solution with various concentrations of
adrenoceptor agonists added. Compared with controls in
Kreb's solution alone, noradrenaline elicited a pronounced
dose-dependent release of 5-HT to the medium, which
increased with incubation time (Figure la). Isoprenaline
caused a much less pronounced release of 5-HT with a
slower time course than NA (Figure Ib). A diluted
suspension of tumour cells (3 x 106cellsml-1) was studied
for 15min after incubation with a calcium ionophore
(A23187 10-5 M), which caused a 5-HT release which
progressively increased with time of incubation (Figure 2).
Thus, the clinical use of calcium and adrenergic drugs should
be strictly avoided; in this patient such combined treatment
may well have been deleterious.
In the present case of the midgut carcinoid syndrome
pretreatment with SMS 201-995 resulted in decreased levels
of one tumour marker (5-HT in peripheral whole blood)
associated with the disappearance of specific symptoms.
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Table I 5-HT levels in peripheral whole blood and 5-HIAA levels in urine of a patient with the carcinoid syndrome during treatment with a
somatostatin analogue.
5-HT levels after PG
(0.6,ugkg-I i.v.)
Basal 5-HT levels postinjection
(ngml-1) 5-HIAA (jumol24h-1)
(<160ngml') 1' 2' 3' (0-50gmol24h ')
Before treatment 856-999 1.000
After SMS (50Mg x 2.s.c.) for 3 days 713-799
After SMS (100jig x 2.s.c.) for 3 more days 230-257 399 684 627
1. Perioperative treatment (surgery):
SMS (I00 g x 4s.c.)+ketanserin (20mg x 2i.v.) for 2 days
Before embolisation of a. hep. sin.
SMS (50jg x 2s.c. for 4 weeks) 180-203 589
2. Perioperative treatment (embolisation): identical with 1
Before embolisation of a. hep. sin. 120-126 129 116 147
SMS (50Mg x 2s.c. for 6 weeks)
3. Perioperative treatment (embolisation): identical with 1 & 2
After complete surgical/embolisation treatment 39-53 51 51 55 320
(I week after cessation of SMS)
NA 10-4 M
NA 10- M
/~~~M .. v^^-6 &A NA U 0 M
control
3-6 minutes 10-13 minutes
12 x 106 cells ml-1
I
L6
A 23187 10-5 M
t.c.
3x106cellsml-1
5 10 15
Time (minutes)
Figure 2 Incubation of a diluted tumour cell suspension with a
calcium ionophore (A 23187, 10-5M) caused a relatively more
pronounced release of 5-HT into the medium than incubation
with an equimolar concentration of NA (cf. Figure 1). Controls
incubated with Kreb's solution alone.
400
C
200
IP 1o-4 M
io-5
control
3-6 minutes 10-13 minutes 17-20 minutes
Figure 1 Tumour cell suspension incubated for 3-20min with
various concentrations of (a) noradrenaline (NA) and (b)
isoprenaline (IP) respectively. Compared with control
suspensions (Kreb's solution alone) NA caused a clear dose-
dependent release of 5-HT into the medium.
When the basal levels of 5-HT were significantly depressed
after 6 days of pretreatment, the patient underwent a
provocation test with PG without subjective discomfort
despite objective release of 5-HT at injection with PG (Table
I). The biochemical outcome of this test suggested blockade
of peripheral 5-HT receptors by SMS 201-995 rather than an
inhibited release of 5-HT. It must be emphasized, however,
that there may be several other tumour products synthesized
by midgut carcinoids besides 5-HT, e.g. peptide hormones of
the tachykinin family, which also are released by PG
(Norheim et al., 1986). These peptides may also cause
carcinoid symptoms. The absence of such symptoms may
thus be due to depressed release and/or blockade of
receptors for such peptides. The clinical outcome of the PG
test with no subjective reaction and stable blood pressure
helped us to decide about surgery during treatment with
SMS 201-995. Since 5-HT was still released after such
blockade, peripheral blockade of 5-HT2-receptors by
ketanserin was added to the treatment. This combined
pharmacological treatment proved to be very effective both
during surgery and subsequent embolisations. Before the
second embolisation the basal levels of 5-HT were almost
normalised and at this stage of treatment the PG test was
biochemically negative, even though the patient had a
considerable tumour burden in the left hepatic lobe. These
observations indicate that the somatostatin analogue now
had blocked both spontaneous and provoked release of 5-
HT in contrast to the findings at the first PG-test (Table I).
Long-term treatment with SMS 201-995 may thus lead to
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effects additional to those seen at acute administration of the
drug.
In conclusion, new synthetic somatostatin analogues may
prove to be important tools to protect patients with
advanced endocrine malignancies against life-threatening
reactions caused by excessive release of tumour-produced
amines and peptides during surgery or hepatic arterial
embolisation. In order to evaluate the efficacy of such
prophylactic treatment, provocation tests with monitoring of
tumour markers may be very useful to obtain an adequate
dosage of the drug.
This study was supported by the Swedish MRC (5220, 2207) and the
MRC of the Swedish Health Insurance Companies.
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